In my previous note, I wrote about replying to a post by Hideo Kageyama (a teacher known for the '100-cell calculation' ...
OneSpan stock is rated Hold after a 35% YTD rise as hardware declines, offset software growth, and margins face pressure.
Medpace is rated a Buy with Q2 revenues rising 17.2% to $707.3M, improving EBITDA margins, and guidance raised for FY26. Read ...
Moody’s RMS Event Response has now provided an initial estimate of insurance industry losses from recent hurricane Isaias, placing them in a range between ...
A Theory of Newtypes Seen in Lionel Messi—The Anomalous Individual Who Strolls and the Extraordinary Ability to Create the ...
Furthermore, we are proposing additional commitments and accountabilities in relation to product pricing and competitiveness of the RAC insurance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results